E-Book Overview
In this innovative and challenging book, William Pardridge, a world leader in the study of the blood-brain barrier and its clinical implications, argues that brain drug development has been restricted by the failure of adequate brain drug targeting. This is an increasingly urgent problem as developments in genomics lead to new generations of therapeutic macromolecules. The author reviews the field of neurotherapeutics from the point of view of drug targeting. He surveys the scientific and clinical basis of drug delivery across biological membranes, including topics such as genetically engineered trojan horses for drug targeting, antisense neurotherapeutics, and gene therapy of brain disorders. At a time when there are few significant new drug treatments in prospect for common neurological diseases, this authoritative review will encourage a wide range of clinicians and neuroscientists to reexamine the development and use of drugs in treating disorders of the central nervous system.
E-Book Content
Brain drug targeting The future of brain drug development
Innovation in the therapeutics of brain disorders depends critically on the delivery of drugs to the appropriate region of the central nervous system, across the blood–brain barrier. The thesis of this innovative and challenging book is that brain drug development has been restricted by the failure of adequate brain drug targeting, and that this is an increasingly urgent problem as developments in genomics lead to new generations of therapeutic macromolecules. The author, a world leader in the study of the blood–brain barrier and its clinical implications, reviews the field of neurotherapeutics from the point of view of drug targeting. He surveys the scientific and clinical basis of drug delivery across biological membranes, including topics such as carrier-mediated transport, receptor-mediated transcytosis, genetically engineered Trojan horses for drug targeting, antisense neurotherapeutics, and gene therapy of brain disorders. At a time when there are few significant new drug treatments in prospect for Alzheimer’s disease, Parkinson’s disease, stroke, brain cancer, or brain injury, this authoritative review will encourage a wide range of clinicians and neuroscientists to reexamine the development and use of drugs in treating disorders of the central nervous system. William M. Pardridge is Professor of Medicine at UCLA School of Medicine and an authority
on the blood–brain barrier. Among his many publications in this field, he is the editor of Introduction to the Blood–Brain Barrier: Methodology, Biology and Pathology (Cambridge University Press, 1998).
Brain drug targeting The future of brain drug development
WILLIAM M. PARDRID GE Professor of Medicine UCLA School of Medicine Los Angeles
The Pitt Building, Trumpington Street, Cambridge, United Kingdom The Edinburgh Building, Cambridge CB2 2RU, UK 40 West 20th Street, New York, NY 10011-4211, USA 10 Stamford Road, Oakleigh, VIC 3166, Australia Ruiz de Alarcón 13, 28014 Madrid, Spain Dock House, The Waterfront, Cape Town 8001, South Africa http://www.cambridge.org © Cambridge University Press 2001 This book is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press. First published 2001 Printed in the United Kingdom at the University Press, Cambridge Typeface Minion 8.5/12pt System QuarkXPress™ [ ] A catalogue record for this book is available from the British Library ISBN 0 521 80077 3 hardback
Every effort has been made in preparing this book to provide accurate and up-to-date information wh